Patients depend on the research and development cycle to produce innovative, life saving medicines for rare and chronic conditions. But this medical innovation faces hurdles if Congress passes medicare price negotiations within the Build Back Better Plan.
Terry and Dr. Bob look at what this means for small, biotech companies creating the cures of tomorrow. And if you’re confused about drug development and pricing, Dr. Ron Cohen of Acorda Therapeutics breaks down the process and what it means for patients.
Plus, get the patient perspective on the importance of rare disease research. Dorothea Lantz is the mom of Hunter, a 4-year old living with Prader-Willi syndrome. She explains why Congress must leave the Orphan Drug Tax Credit alone in order to protect the development of future treatments that could help patients like Hunter.
Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest
Kate Pecora, Field Correspondent, Patients Rising
Katie Moureau, Patient Correspondent
Nichole McLaud, Patient Correspondent
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: firstname.lastname@example.org
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.